Market capitalization | $118.22m |
Enterprise Value | $179.07m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 8.51 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-129.11m |
Free Cash Flow (TTM) Free Cash Flow | $-148.99m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
7 Analysts have issued a Seres Therapeutics Inc forecast:
7 Analysts have issued a Seres Therapeutics Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -7.48 -7.48 |
107%
107%
|
|
EBITDA | -122 -122 |
32%
32%
|
EBIT (Operating Income) EBIT | -129 -129 |
20%
20%
|
Net Profit | -147 -147 |
29%
29%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Eric Shaff |
Employees | 103 |
Founded | 2010 |
Website | www.serestherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.